WINT: Windtree Therapeutics Price to Sales

Symbol and logo of brand Windtree (WINT)

The Windtree Therapeutics (WINT) P/S ratio, as shown on this GURU.Markets chart, allows for a valuation of the business relative to revenue generated from developing drugs for cardiac and pulmonary pathologies, with the value reflecting the current figure. The company's growth relies on synergy with cardiac centers during drug testing. Low geopolitical risks ensure operational stability within Western legal frameworks.

WINT: Windtree Therapeutics Market Cap to Revenue 07/04/2022 - 11/13/2026

Analytical breakdowns for Windtree Therapeutics (WINT)

- current quotes and average value forecast:
Market Price windtreetx.com|WINT - Analyst Consensus Forecast
- market capitalization information:
Market Value Windtree|WINT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Windtree Therapeutics|WINT - Company Net Assets|Market Cap to Book Value Multiple windtreetx.com|WINT - Company Total Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Windtree Therapeutics|WINT - Long-Term Debt to Capital|Current Liabilities to Capital windtreetx.com|WINT - Company Debts|Debt to Net Assets Ratio Windtree|WINT - Company Long-Term Debts|Company Short-Term Debts Windtree Therapeutics|Critical Liquidity Ratio windtreetx.com
- earnings and valuation multiples information:
WINT - Net Profit|Expected Net Profit Windtree Therapeutics|WINT - Price to Earnings Ratio|Forward P/E Multiple windtreetx.com|WINT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Windtree|WINT - Operating profit EBITDA|Net earnings per share for the last four quarters Windtree Therapeutics|WINT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months windtreetx.com|WINT - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Windtree Therapeutics
- sales revenue and business income indicators:
WINT - Company Sales|Company Future Sales Volume windtreetx.com|WINT - P/S Multiple|Market Cap to Expected Sales Ratio Windtree
Fundamental company analysis:Windtree Therapeutics Inc., WINT
Finished products of Windtree

For Windtree Therapeutics (WINT), whose heart failure therapy patents are losing value due to FDA failures, a market value analysis relative to revenue via the revenue multiple reveals a genuine valuation imbalance. The current value of is calculated as the ratio of market capitalization to annual revenue, allowing investors to determine if the company is overvalued amid a chronic shortage of R&D capital.

Competing companies

REGN - Price to Sales|P/S Multiple IRTC (iRhythm)|Lantheus Holdings (LNTH) - Price to Sales|MLYS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HTFL (Heartflow Inc)|KMTS (Kestra Medical Technologies) - Market Cap to Revenue|ESPR: Market Cap to Sales Volume|AMRN (Amarin) - P/S Multiple|AVR: Market Capitalization-to-Revenue Ratio|P/S Multiple TNYA|CVRX - Price to Sales|Price-to-Revenue Ratio Milestone Pharmaceuticals MIST|Market Capitalization-to-Revenue Ratio CRDL|HeartBeam - P/S Multiple|TENX - P/S Multiple|Adagio Medical Holdings Inc. (ADGM) - Price-to-Revenue Ratio|Price-to-Sales Ratio BCDA (BioCardia Inc)|VTAK (Catheter Precision) - P/S Multiple|Price to Sales ARCA Bio ABIO|Market Cap to Revenue ACST (Acasti Pharma)|P/S Multiple Aerovate Therapeutics Inc. (AVTE)|Verve Therapeutics, Inc. - Market Cap to Revenue